Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05147402 · ClinicalTrials.gov registry record · Phase 1
Food Effects on Bioavailability of MDMA in Healthy Volunteers
A Phase 1 study, sponsored by Resilient Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT05147402: Completed Phase 1 study, sponsored by Resilient Pharmaceuticals.
NCT05147402 is a Phase 1 study that has completed, run by Resilient Pharmaceuticals. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05147402, a Phase 1 study, has completed, sponsored by Resilient Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if food impacts absorption of MDMA in participants who are either fed or fasted. The main question it aims to answer is: What is the effect of eating food on the safety of taking oral MDMA? Researchers will compare participants who are fasted for 10 hours to participants who are fed a high-fat and high-calorie meal. Participants will be randomized to either the fed or fasted group, then be administered MDMA. Vitals and blood samples will be taken. Then, participants will be assigned to the opposite condition and vitals and blood samples will be taken.
Interventions
- DRUG midomafetamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-07-28 |
| Est. Completion | 2022-12-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05147402
The ClinicalTrials.gov registry entry for NCT05147402 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Resilient Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which midomafetamine is the first listed.
NCT05147402 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05147402 about?
NCT05147402 is a clinical study titled "Food Effects on Bioavailability of MDMA in Healthy Volunteers". The goal of this clinical trial is to learn if food impacts absorption of MDMA in participants who are either fed or fasted. The main question it aims to answer is: What is the effect of eating food on the safety of taking oral MDMA? Researchers will compare participants who are fasted for 10 hour...
What is the current status of trial NCT05147402?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2022-07-28. Estimated completion is 2022-12-05.
What interventions are being tested in trial NCT05147402?
The interventions under investigation include: midomafetamine (DRUG).
Who is sponsoring clinical trial NCT05147402?
This trial is sponsored by Resilient Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.